The results of a nine-month investigation by health regulators in the European Union should be comforting for anyone taking Ozempic and other similar drugs to treat type 2 diabetes and/or obesity. EU officials said Friday that they failed to find evidence of a causative link between GLP-1 drugs and an increased risk…